Targeting SPARC by lentivirus-mediated RNA interference inhibits cervical cancer cell growth and metastasis

BMC Cancer

Jie Chen¹  Dehuan Shi³  Xiaoyan Liu³  Shuang Fang⁴  Jie Zhang²  Yueran Zhao² 

[1] Department of Maternal and Child Health Care, School of Public Health, Shandong University, Jinan, 250012, China

[2] Central Laboratory, Shandong Provincial Hospital affiliated to Shandong University, Jinan, 250021, China

[3] Department of Obstetrics and Gynecology, Qilu Hospital, Shandong University, Jinan, 250012, China

[4] Major of Clinical Medicine, Preclinical Medicine College, Taishan Medical University, Taian, 271000, China

关键词: Metastasis;    Apoptosis;    Proliferation;    Cervical cancer;    SPARC;   

Others  :  1080145
DOI  :  10.1186/1471-2407-12-464

 received in 2012-04-11, accepted in 2012-10-08,  发布年份 2012

【 摘 要 】

Background

Secreted protein acidic and rich in cysteine (SPARC), a calcium-binding matricellular glycoprotein, is implicated in the progressions of some cancers. However, no information has been available to date regarding the function of SPARC in cervical cancer cell growth and metastasis.

Methods

In this study, we isolated and established high invasive subclones and low invasive subclones from human cervical cancer cell lines HeLa and SiHa by the limited dilution method. Real-time q-RT-PCR, Western Blot and ICC were performed to investigate SPARC mRNA and protein expressions in high invasive subclones and low invasive subclones. Then lentivirus vector with SPARC shRNA was constructed and infected the highly invasive subclones. Real-time q-RT-PCR, Western Blot and ICC were also performed to investigate the changes of SPARC expression after viral infection. In functional assays, effects of SPARC knockdown on the biological behaviors of cervical cancer cells were investigated. The mechanisms of SPARC in cervical cancer proliferation, apoptosis and invasion were also researched.

Results

SPARC was over-expressed in the highly invasive subclones compared with the low invasive subclones. Knockdown of SPARC significantly suppressed cervical cancer cell proliferation, and induced cell cycle arrest at the G1/G0 phase through the p53/p21 pathway, also caused cell apoptosis accompanied by the decreased ratio ofBcl-2/Bax, and inhibited cell invasion and metastasis accompanied by down-regulated MMP2 and MMP9 expressions and up-regulated E-cadherin expression.

Conclusion

SPARC is related to the invasive phenotype of cervical cancer cells. Knockdown of SPARC significantly suppresses cervical cancer cell proliferation, induces cell apoptosis and inhibits cell invasion and metastasis. SPARC as a promoter improves cervical cancer cell growth and metastasis.

【 授权许可】

   
2012 Chen et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

Figure 4.

Figure 5.

Figure 6.

Figure 7.

Figure 8.

【 参考文献 】

• [1]Parkin DM, Bray FI, Devesa SS: Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001, 37(Suppl 8):S4-66.
• [2]Waggoner SE: Cervical cancer. Lancet 2003, 361:2217-2225.
• [3]Sheng X, Du X, Zhang X, et al.: Clinical value of serum SPARC levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat Med J 2009, 50(5):455-464.
• [4]Rao Y, Wang H, Fan L, et al.: Silencing MTA1 by RNAi reverses adhesion, migration and invasiveness of cervical cancer cells (SiHa) via altered expression of p53, and E-cadherin/β-catenin complex. J Huazhong Univ Sci Technolog Med Sci 2011, 31(1):1-9.
• [5]Shibata K, Kajiyama H, Ino K, et al.: Twist expression in patients with cervical cancer is associated with poor disease outcome. Ann Oncol 2008, 19(1):81-85.
• [6]Termine JD, Kleinman HK, Whitson SW, et al.: Osteonectin, a bone-specific protein linking mineral to collagen. Cell 1981, 26:99-105.
• [7]Bornstein P, Sage EH: Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002, 14(5):608-616.
• [8]Chlenski A, Cohn SL: Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol 2010, 21(1):55-65.
• [9]Tai IT, Tang MJ: SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 2008, 11(6):231-246.
• [10]Albini A, Iwamoto Y, Kleinman HK, et al.: A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987, 47(12):3239-3245.
• [11]Framson PE, Sage EH: SPARC and tumor growth: where the seed meets the soil? J Cell Biochem 2004, 92:679-690.
• [12]Hsiao YH, Lien HC, Hwa HL, et al.: SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J 2010, 16(3):305-308.
• [13]Lien HC, Hsiao YH, Lin YS, et al.: Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 2007, 26(57):7859-7871.
• [14]Horie K, Tsuchihara M, Nakatsura T: Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci 2010, 101(4):913-919.
• [15]Girotti MR, Fernández M, López JA, et al.: SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis. J Invest Dermatol 2011, 131(12):2438-2447.
• [16]Lau CP, Poon RT, Cheung ST, et al.: SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol 2006, 210(4):459-468.
• [17]Le Bail B, Faouzi S, Boussarie L, et al.: Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol 1999, 189(1):46-52.
• [18]Thomas R, True LD, Bassuk JA, et al.: Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000, 6(3):1140-1149.
• [19]Chan SK, Griffith OL, Tai IT, et al.: Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev 2008, 17(3):543-552.
• [20]Wiese AH, Auer J, Lassmann S, et al.: Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect Prev 2007, 31(4):282-295.
• [21]Nagai MA, Gerhard R, Fregnani JH, et al.: Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 2011, 126(1):1-14.
• [22]Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, et al.: Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 2005, 65(16):7370-7377.
• [23]Said N, Motamed K: Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 2005, 167(6):1739-1752.
• [24]Said N, Najwer I, Motamed K: Secreted protein acidic and rich in cysteine (SPARC) inhibits integrinmediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol 2007, 170(3):1054-1063.
• [25]Atorrasagasti C, Malvicini M, Aquino JB, et al.: Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells. Int J Cancer 2010, 126(11):2726-2740.
• [26]Said N, Frierson HF Jr, Chernauskas D, et al.: The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene 2009, 28(39):3487-3498.
• [27]Liang JF, Wang HK, Xiao H, et al.: Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res 2010, 29:71. BioMed Central Full Text
• [28]Yang E, Kang HJ, Koh KH, et al.: Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 2007, 121(3):567-575.
• [29]Sova P, Feng Q, Geiss G, et al.: Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 2006, 15(1):114-123.
• [30]Kahn SL, Ronnett BM, Gravitt PE, et al.: Quantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap tests. Cancer 2008, 114(1):57-64.
• [31]Zhang LQ, Jiang F, Xu L, et al.: The Role of Cyclin D1 Expression and Patient's Survival in Non-Small-Cell Lung Cancer: A Systematic Review with Meta-Analysis. Clin Lung Cancer 2012, 13(3):188-195.
• [32]Naryzhny SN: Proliferating cell nuclear antigen: a proteomics view. Cell Mol Life Sci 2008, 65(23):3789-3808.
• [33]Liebermann DA, Hoffman B, Vesely D: p53 induced growth arrest versus apoptosis and its modulation by survival cytokines. Cell Cycle 2007, 6:166-170.
• [34]Gartel AL: p21 (WAF1/CIP1) and cancer: a shifting paradigm? Biofactors 2009, 35(2):161-164.
• [35]Fenouille N, Robert G, Tichet M, et al.: The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression. Pigment Cell Melanoma Res 2011, 24(1):219-232.
• [36]Kelly PN, Strasser A: The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011, 18(9):1414-1424.
• [37]Fenouille N, Puissant A, Tichet M, et al.: SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene 2011, 30(49):4887-4900.
• [38]Robert G, Gaggioli C, Bailet O, et al.: SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res 2006, 66(15):7516-7523.
• [39]Smit DJ, Gardiner BB, Sturm RA: Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. Int J Cancer 2007, 121(12):2653-2660.
• [40]Kunigal S, Gondi CS, Gujrati M, et al.: SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol 2006, 29(6):1349-1357.
• [41]McClung HM, Thomas SL, Osenkowski P, et al.: SPARC Upregulates MT1-MMP Expression, MMP-2 Activation, and the Secretion and Cleavage of Galectin-3 in U87MG Glioma Cells. Neurosci Lett 2007, 419(2):172-177.